Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus

Current Atherosclerosis Reports

Volumn 14, Issue 1, 2012, Pages 60-69

  Igel, Leon I ^a   Powell, Amanda G ^b   Apovian, Caroline M ^b   Aronne, Louis J ^c  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Glycemic control; Obesity; Pharmacotherapy; Type 2 diabetes; Weight loss; Weight management; Weight centric management of type 2 diabetes

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; DAPAGLIFLOZIN; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; INSULIN GLARGINE; LEPTIN; LIRAGLUTIDE; LORCASERIN; METFORMIN; METRELEPTIN; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; PRAMLINTIDE; SALSALATE; SITAGLIPTIN; SULFONYLUREA; TETRAHYDROLIPSTATIN;

ARTICLE; COMORBIDITY; CONSTIPATION; DISEASE MODEL; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GENITAL TRACT INFECTION; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARESTHESIA; VALVULAR HEART DISEASE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; HUMANS; LIFE STYLE; OBESITY; OVERWEIGHT; RISK FACTORS; WEIGHT LOSS;

EID: 84857629070     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-011-0221-0     Document Type: Article

References (57)

1. American Heart Association. Overweight and Obesity Statistics - 2009 Update. Available at: http://www.americanheart.org/downloadable/heart/ 1236358025411OVRWGHT.pdf
2. KM Flegal MD Carroll, et al. 2010 Prevalence and trends in obesity among US adults, 1999-2008 JAMA. 303 3 235 241 20071471 10.1001/jama.2009.2014 1:CAS:528:DC%2BC3cXptVyksA%3D%3D The authors examined trends in obesity from 1999 through 2008 and also assessed the prevalence of obesity and overweight for 2007-2008. The authors found a very high prevalence of obesity in the US (32.2% among adult men and 35.5% among adult women).
3. JG Trogdon FinkelsteinEA, et al. 2009 Annual medical spending attributable to obesity: payer-and service-specific estimates Heal Aff 28 5 w822 w831 10.1377/hlthaff.28.5.w822 Available at: http://content.healthaffairs.org/ cgi/reprint/28/5/w822
4. United Health Foundation. America's Health Rankings -20th Anniversary highlights (2010). Available at: http://www.americashealthrankings.org/2009/ highlights.aspx
5. Aronne LJ. A practical guide to drug-induced weight gain. Minneapolis: McGraw-Hill; 2002. p. 77-91.
6. HC Gerstein ME Miller RP Byington, et al. 2008 Effects of intensive glucose lowering in type 2 diabetes N Engl J Med. 358 24 2545 2559 18539917 10.1056/NEJMoa0802743 1:CAS:528:DC%2BD1cXnt1Wjs7s%3D The authors examined whether intensive glucose lowering therapy targeting normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors. The authors found that intensive glucose lowering therapy actually increased mortality and did not significantly reduce major cardiovascular events in this high-risk population. (Pubitemid 351831356)
7. JW Anderson EC Konz 2001 Obesity and disease management: effects of weight loss on comorbid conditions Obes Res 9 326S 334S 11707561 10.1038/oby.2001.138
8. NHLBI Obesity Education Initiative Working Group: The Practical Guide: Identification, Evaluation and Treatment of Overweight and Obesity in Adults. NIH/NHLBI/NAASO; October 2000. NIH Publication 00 -4084
9. AB Goldfine V Fonseca KA Jablonski, et al. 2010 The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial Ann Intern Med. 152 6 346 357 20231565
10. Koska J, Ortega E, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia, Springer Berlin/Heidelberg. 2009;52:385-93.
11. Over-the-counter weight loss with orlistat? Drug Ther Bull. 2009;47(11):125-127.
12. JS Torgerson J Hauptman, et al. 2004 XENical in the prevention of diabetes in obese subjects (XENDOS) study Diabetes Care 27 1 155 161 14693982 10.2337/diacare.27.1.155 1:CAS:528:DC%2BD2cXmvV2jug%3D%3D (Pubitemid 38196725)
13. Genentech USA, Inc. Xenical (Orlistat) Package Insert. Revised December 2010. http://www.gene.com/gene/products/information/xenical/pdf/pi.pdf
14. J Hauptman, et al. 2000 Orlistat in the long-term treatment of obesity in primary care settings Arch Fam Med 9 160 167 10693734 10.1001/archfami.9.2.160 1:STN:280:DC%2BD3c7lsFCjsw%3D%3D
15. S Rössner, et al. 2000 Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity Obes Res 8 49 61 10678259 10.1038/oby.2000.8
16. Bristol-Myers Squibb Company, Glucophage (metformin) package insert. Rev. January 2009 http://packageinserts.bms.com/pi/pi-glucophage.pdf
17. WC Knowler, et al. 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 6 393 403 11832527 10.1056/NEJMoa012512 1:CAS:528:DC%2BD38XhtVWqurc%3D (Pubitemid 34437694)
18. RA DeFronzo AM Goodman 1995 Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus NEJM 333 9 541 549 7623902 10.1056/NEJM199508313330902 1:CAS:528:DyaK2MXpsVanurY%3D
19. AC Robinson J Burke, et al. 1998 The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control Diabetes Care. 21 5 701 705 9589227 10.2337/diacare.21.5.701 1:STN:280:DyaK1c3ltFWiuw%3D%3D (Pubitemid 28487058)
20. MG Wulffele A Kooy D de Zeeuw, et al. 2004 The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review J Intern Med 256 1 14 15189360 10.1111/j.1365-2796.2004.01328.x 1:CAS:528:DC%2BD2cXmtVSjur4%3D (Pubitemid 38813614)
21. The Look AHEAD Research Group 2010 Long term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes: four year results of the Look AHEAD trial Arch Intern Med. 170 17 1566 1575 10.1001/archinternmed.2010.334 The authors examined the effects of intensive lifestyle intervention as compared to a control condition of diabetes support and education on changes in weight, fitness, and cardiovascular disease risk factors in 5145 overweight or obese subjects with type 2 diabetes over 4 years. They found that intensive lifestyle intervention produced sustainable weight loss as well as improvements in fitness, glycemic control, and cardiovascular disease risk factors.
22. Amylin Pharmaceuticals and Eli Lilly & Company. Byetta Package Insert. Rev: September 2010 http://pi.lilly.com/us/byetta-pi.pdf
23. T Moretto D Milton, et al. 2008 Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study Clin Ther 30 8 1448 1460 18803987 10.1016/j.clinthera.2008.08.006 1:CAS:528:DC%2BD1cXhtF2rtLfE
24. RA DeFronzo RE Ratner J Han DD Kim MS Fineman AD Baron 2005 Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes mellitus Diabetes Care 28 1092 1100 15855572 10.2337/diacare.28.5.1092 1:CAS:528:DC%2BD2MXksF2hu7g%3D (Pubitemid 40616618)
25. JB Buse RR Henry J Han DD Kim MS Fineman AD Baron 2004 Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 27 2628 2635 15504997 10.2337/diacare.27.11.2628 1:CAS:528:DC%2BD2cXhtVKis7zO (Pubitemid 39441462)
26. DM Kendall MC Riddle J Rosenstock, et al. 2005 Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes mellitus treated with metformin and a sulfonylurea Diabetes Care 28 1083 1091 15855571 10.2337/diacare.28.5.1083 1:CAS:528:DC%2BD2MXksF2hu7s%3D (Pubitemid 40616617)
27. L Blonde EJ Klein, et al. 2006 Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes Diabetes Obes Metab 8 4 436 447 16776751 10.1111/j.1463-1326.2006.00602.x 1:CAS:528:DC%2BD28XnsFWhsLc%3D (Pubitemid 44349236)
28. JB Buse DC Klonoff, et al. 2007 Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo controlled trials Clin Ther. 29 139 153 17379054 10.1016/j.clinthera.2007.01.015 1:CAS:528: DC%2BD2sXjsVOns7w%3D (Pubitemid 46414034)
29. ES Horton C Silberman, et al. 2010 Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database Diabetes Care 33 8 1759 1765 20460445 10.2337/dc09-2062 1:CAS:528:DC%2BC3cXhtFahs7jJ
30. Merck & Co., INC. Januvia (Sitagliptin) Package Insert. 9984404. Revised 2010. Available at: http://www.merck.com/product/usa/pi-circulars/j/ januvia/januvia-pi.pdf
31. G Bray 2009 Gastrointestinal hormones and weight management Lancet. 374 9701 1570 1571 19853907 10.1016/S0140-6736(09)61560-9
32. D Russell-Jones, et al. 2009 Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue Mol Cell Endocrinol. 297 1-2 137 140 19041364 10.1016/j.mce.2008.11.018 1:CAS:528:DC%2BD1cXhsFajt73I
33. A Garber R Henry R Ratner, et al. 2009 Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 373 473 481 18819705 10.1016/S0140-6736(08)61246-5 1:CAS:528:DC%2BD1MXhsFKgur0%3D The authors investigated the safety and efficacy of liraglutide as monotherapy as compared to glimepiride monotherapy in 746 subjects with type 2 diabetes over 52 weeks. They found that liraglutide was effective in the treatment of type 2 diabetes mellitus and led to greater reductions in HbA1c, weight, and blood pressure than did glimepiride without the risk of hypoglycemia.
34. MA Nauck A Frid K Hermansen, et al. 2009 Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes Diabetes Care 32 84 90 18931095 10.2337/dc08-1355 1:CAS:528:DC%2BD1MXhs1Ggu7g%3D
35. T Blevins J Pullman J Malloy P Yan K Taylor C Schulteis, et al. 2011 J Clin Endocrinol Metab. 96 1301 1310 21307137 10.1210/jc.2010-2081 1:CAS:528:DC%2BC3MXmsVWnsro%3D Epub 2011 Feb 9. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
36. Amylin Pharmaceuticals. Symlin (pramlintide) Package Insert. 812003-CC Revised July 2008. Available at: https://www.symlin.com/pdf/SYMLIN-pi-combined. pdf
37. RE Ratner R Dickey M Fineman, et al. 2004 Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year randomized controlled trial Diabet Med 11 1204 1212 10.1111/j.1464-5491.2004.01319.x (Pubitemid 39472376)
38. LM Younk M Mikeladze, et al. 2011 Pramlintide and the treatment of diabetes: a review of the data since its introduction Expert Opin Pharmacother 12 9 1439 1451 21564002 10.1517/14656566.2011.581663 1:CAS:528: DC%2BC3MXmtFaktLc%3D
39. PA Hollander P Levy MS Fineman, et al. 2003 Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial Diabetes Care 3 784 790 10.2337/diacare.26.3.784 (Pubitemid 36929344)
40. L Aronne, et al. 2007 Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study J Clin Endocrinol Metab 92 8 2977 2983 17504894 10.1210/jc.2006-2003 1:CAS:528:DC%2BD2sXptl2hs7c%3D (Pubitemid 47236359)
41. Aronne LJ, Isoldi KK, Roarke DT. The Johns Hopkins University textbook of dyslipidemia chapter 24: therapeutic options for modifying obesity and cardiometabolic risk factors. Kwiterovich PO, editor. Lippincott, Williams and Wilkins; 2009. pp. 277-91.
42. SR Smith, et al. 2008 Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity Diabetes Care 31 9 1816 1823 18753666 10.2337/dc08-0029
43. E Ravussin SR Smith, et al. 2009 Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy Obesity 17 9 1736 1743 19521351 10.1038/oby.2009.184 1:CAS:528:DC%2BD1MXhtVKkurnF
44. Amylin Pharmaceuticals press release July 9, 2009. Amylin Pharmaceuticals Announces Positive Results from dose ranging clinical study of Pramlintide/Metreleptin Combination Treatment for Obesity. Available at: http://phx.corporate-ir.net/phoenix.zhtml?c=101911&p=irol- newsArticle&ID=1305954
45. Amylin Pharmaceuticals press release October 1, 2008. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of the Obesity Society. Available at: http://phx.corporate-ir.net/phoenix.zhtml?c=101911&p=irol- newsArticle&ID=1204556&highlight
46. LM Kaplan 2005 Pharmacologic therapies for obesity Gastroenterol Clin N Am 39 1 69 79 10.1016/j.gtc.2010.01.001
47. CK Haddock WS Poston PL Dill JP Foreyt M Ericsson 2002 Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials Int J Obes Relat Metab Disord. 26 262 273 11850760 10.1038/sj.ijo.0801889 1:CAS:528:DC%2BD38XitVClsLs%3D (Pubitemid 34151206)
48. Z Li M Maglione W Tu, et al. 2005 Meta-analysis: pharmacologic treatment of obesity Ann Intern Med. 142 532 546 15809465 1:CAS:528:DC%2BD2MXjslCqsL8%3D
49. GA Bray DH Ryan 2007 Drug treatment of the overweight patient Gastroenterology 132 2239 2252 17498515 10.1053/j.gastro.2007.03.053 1:CAS:528:DC%2BD2sXmsVyns7c%3D (Pubitemid 46693746)
50. Hendricks EJ, Greenway FL, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring). 2011 Apr 28. [Epub ahead of print].
51. KM Gadde, et al. 2011 Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial Lancet 377 9774 1341 1352 21481449 10.1016/S0140-6736(11)60205-5 1:CAS:528:DC%2BC3MXkvVSqtL4%3D The authors assessed the efficacy and safety of phentermine plus topiramate controlled-release combination in 2487 individuals who were overweight and obese with two or more risk factors. They found that phentermine plus topiramate produced significant weight loss as well as improvement in many metabolic risk factors over the 56 weeks of the trial.
52. FL Greenway K Fujioka, et al. 2010 Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet. 376 9741 595 605 20673995 10.1016/S0140-6736(10)60888-4 1:CAS:528:DC%2BC3cXhtVGmtbbK The authors assessed the effect of sustained-release naltrexone and bupropion on bodyweight in 1742 overweight and obese subjects and found that the combination promoted significant weight loss as well as improvements in many metabolic risk factors.
53. SR Smith NJ Weissman, et al. 2010 Multicenter, placebo-controlled trial of lorcaserin for weight management N Engl J Med. 363 3 245 256 20647200 10.1056/NEJMoa0909809 1:CAS:528:DC%2BC3cXptVOgs74%3D The authors evaluated the use lorcaserin as compared to placebo in 3182 overweight and obese adults over 52 weeks. They found that lorcaserin promoted significant weight loss as well as improvements in many metabolic risk factors.
54. K Katsuno Y Fujimori Y Takemura M Hiratochi F Itoh Y Komatsu, et al. 2007 Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level J Pharmacol Exp Ther 320 323 330 17050778 10.1124/jpet.106.110296 1:CAS:528:DC%2BD2sXjsFCiug%3D%3D (Pubitemid 46025747)
55. CJ Bailey JL Gross, et al. 2010 Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial Lancet 375 9733 2223 2233 20609968 10.1016/S0140-6736(10)60407-2 1:CAS:528:DC%2BC3cXotVagtro%3D The authors evaluated the adjunct use of dapagliflozin in 546 individuals with type 2 diabetes treated with metformin over 24 weeks. They found that dapagliflozin promoted significant weight loss as well as improved glycemic and blood pressure control.
56. Musso G, Gambino R, et al. A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann Med. 2011; Apr 15. [Epub ahead of print]1-19.
57. AT Siram R Yanagisawa M Skamagas 2010 Weight management in type 2 diabetes mellitus Mount Sinai J Med 77 533 548 10.1002/msj.20208